Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.

There is no more extensive information

Inclusion Criteria:

• patients with a confirmed diagnosis of ALS according to El Escorial criteria. Diagnosis-time less than four years.
• Over 18 years old. Forced vital capacity ≥ 40%.
• One year of evolution.
• Adequate nutritional state

Exclusion Criteria:

• Severe bulbar ALS involucre.
• Inadequate nutritional status.
• Spondylotic myelopathy, or abnormalities in imaging study.
• Having concomitant neurological or psychiatric disease.
• Systemic disease with poor-control.
• History of treatment with steroids or immunoglobulins in the last year.
• Participate in the past three months in a Clinical Trial.
• History of malignancy or cancer today.
• Intracranial hypertension.
• Clinical suggestive data of infection in the site of lumbar puncture.
• Tracheostomy.
• Use of mechanical ventilation. Forced vital capacity less than 40%. HIV-seropositive or presence of antibodies against hepatitis B or C in the serological studies.